Ventilator Associated Pneumonia ( VAP)AI-VAPNCT06917521
VAP Identification by AI
An observational study of Ventilator Associated Pneumonia ( VAP), run by Ente Ospedaliero Cantonale, Bellinzona at 1 site in Switzerland.
Trial summary
Ventilator-associated pneumonia (VAP) is the most frequent infection in the intensive care setting. For VAP there is currently no reliable diagnostic criteria. We aimed with the present study, using data from the mechanical ventilator to identify early this infection using artificial intelligence methods . Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ventilator Associated Pneumonia ( VAP)
- How many people
- 76 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jul 2023to 15 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All consecutive adult patients admitted to our ICU requiring invasive respiratory support for at least 48 hours will be enrolled
Who may be able to join
- adult patients admitted to our ICU requiring invasive respiratory support for at least 48 hours
Who cannot join
- previuos pneumonia
Trial locations and contacts
1 site in 1 country.
About this study
Official title: EARLY IDENTIFICATION OF VENTILATOR ASSOCIATED PNEUMONIA USING MACHINE LEARNING TECHNIQUES: A PROSPECTIVE COHORT
Ventilator-associated pneumonia (VAP) is the most frequent infection in the intensive care setting. For VAP there is currently no reliable diagnostic criteria. We aimed with the present study, using data from the mechanical ventilator to identify early this infection using artificial intelligence methods .
Read the detailed description
Ventilator-associated pneumonia (VAP) is defined as a hospital-acquired pneumonia occurring in patients submitted to invasive mechanical ventilation (MV) for at least 48 hours. VAP represents the most prevalent nosocomial infection in the intensive care setting. VAP is burdened by prolonged duration of MV and hospital length of stay and consequently increases hospital costs. Moreover, mortality and antibiotic use are also significantly affected. Unfortunately, there is currently no valid, accurate diagnostic criteria of VAP because even the most widely used ones are neither sensitive nor specific.. The insufficient sensitivity of these criteria to rule out VAP carries the risk of antibiotic overuse with the consequently emerging of antibiotic resistance and superinfections. On the other hand, the insufficient specificity to rule in VAP carries the risk of delayed administration of antimicrobial therapy leading to increased mortality. Ventilator-associated event surveillance failed to accurately identify VAP, too . The purpose of the present study is to develop different AI-algorithms using data continuously recorded form the mechanical ventilator in supporting clinicians for the early detection of VAP. An accurate AI-algorithm for early VAP identification has the potential to reduce morbidity, mortality, exposure to broad-spectrum and/or unnecessary antibiotics and finally to reduce costs.
- Conditions
- Ventilator Associated Pneumonia ( VAP)
- Medical subject headings
- Pneumonia, Ventilator-Associated
What is being measured
The primary outcome is the main question the study is designed to answer.
Early identification of VAP
Sensitivity, specificity, AUROC and AUPRC
Measured: From July 2023 to Mars 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2025
- Study start1 Jul 2023
- Primary completion1 Mar 2025
- Study completion15 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ventilator Associated Pneumonia ( VAP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 76 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ente Ospedaliero Cantonale, Bellinzona
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06917521
- Sponsor's protocol ID
- 2022-00624 CE 4085
- Acronym
- AI-VAP
- Status last verified
- Aug 2025
- First submitted
- 1 Apr 2025
- Last updated
- 24 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EARLY IDENTIFICATION OF VENTILATOR ASSOCIATED PNEUMONIA USING MACHINE LEARNING TECHNIQUES: A PROSPECTIVE COHORT
- ClinicalTrials.gov ID
- NCT06917521
- Acronym / sponsor ID
- AI-VAP / 2022-00624 CE 4085
- Conditions
- Ventilator Associated Pneumonia ( VAP)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 76 participants (actual)
- Lead sponsor
- Ente Ospedaliero Cantonale, BellinzonaUniversity, hospital or other
- Study start
- 1 Jul 2023 (actual)
- Primary completion
- 1 Mar 2025 (actual)
- Study completion
- 15 Jun 2025 (actual)
- First posted
- 8 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ventilator-associated pneumonia (VAP) is the most frequent infection in the intensive care setting. For VAP there is currently no reliable diagnostic criteria. We aimed with the present study, using data from the mechanical ventilator to identify early this infection using artificial intelligence methods .
Detailed description
Ventilator-associated pneumonia (VAP) is defined as a hospital-acquired pneumonia occurring in patients submitted to invasive mechanical ventilation (MV) for at least 48 hours. VAP represents the most prevalent nosocomial infection in the intensive care setting. VAP is burdened by prolonged duration of MV and hospital length of stay and consequently increases hospital costs. Moreover, mortality and antibiotic use are also significantly affected. Unfortunately, there is currently no valid, accurate diagnostic criteria of VAP because even the most widely used ones are neither sensitive nor specific.. The insufficient sensitivity of these criteria to rule out VAP carries the risk of antibiotic overuse with the consequently emerging of antibiotic resistance and superinfections. On the other hand, the insufficient specificity to rule in VAP carries the risk of delayed administration of antimicrobial therapy leading to increased mortality. Ventilator-associated event surveillance failed to accurately identify VAP, too . The purpose of the present study is to develop different AI-algorithms using data continuously recorded form the mechanical ventilator in supporting clinicians for the early detection of VAP. An accurate AI-algorithm for early VAP identification has the potential to reduce morbidity, mortality, exposure to broad-spectrum and/or unnecessary antibiotics and finally to reduce costs.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All consecutive adult patients admitted to our ICU requiring invasive respiratory support for at least 48 hours will be enrolled
Key inclusion criteria (1 listed)
- adult patients admitted to our ICU requiring invasive respiratory support for at least 48 hours
Key exclusion criteria (1 listed)
- previuos pneumonia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Early identification of VAP
Time frame: From July 2023 to Mars 2025
Sensitivity, specificity, AUROC and AUPRC
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Ventilator Associated Pneumonia ( VAP)
Not yet recruitingObservational study
Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS
VAP - Ventilator Associated Pneumonia
Recruiting
Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia
Ventilator-Associated Pneumonia (VAP)
Recruiting
Effect of Ventilator Hyperinflation Combined With Body Positioning on ABG in VAP
Ventilator Associated Bacterial Pneumonia (VABP), Critical Illness
Active, not recruiting
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
HAP - Hospital Acquired Pneumonia, VAP - Ventilator Associated Pneumonia
RecruitingPhase 4
Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Therapy in Critically Ill Patients With Ventilator-associated Pneumonia
Ventilator Associated Pneumonia ( VAP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ventilator Associated Pneumonia ( VAP), run by Ente Ospedaliero Cantonale, Bellinzona at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Early identification of VAP (time frame: From July 2023 to Mars 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2025.